11 results about "Fangchinoline" patented technology

The invention discloses a CYP450 enzyme CYP80Q4 participating in biological synthesis of stephania tetrandra alkaloid and application of the CYP450 enzyme CYP80Q4. According to the technical scheme, the cytochrome P450 enzyme from stephania tetrandra is applied to catalysis of a C-O coupling reaction of a compound to generate bisbenzylisoquinoline alkaloid, the name of the protein is CYP80Q4, and the amino acid sequence is a sequence 2 in a sequence table. After a CYP80Q4 gene is expressed in yeast, a microsome extracting solution containing CYP80Q4 protein is extracted, substrates are screened through a substrate spectrum enzymatic reaction, and 10 groups of obtained substrates can be subjected to a C-O coupling reaction under the catalysis of CYP80Q4 enzyme to generate the bisbenzylisoquinoline alkaloid. The method can be applied to the biosynthesis of the dibenzylisoquinoline alkaloid and / or the effective component tetrandrine of the stephania tetrandra, and the breeding of the stephania tetrandra.

The present invention provides the use of fangchinoline in preparing a drug for treating STAG2 mutation acute myeloid leukemia, and relates to the field of leukemia therapeutics. The use of fangchinoline in preparing a drug for treating STAG2 mutation acute myeloid leukemia according to the present invention addresses the problems of high incidence, poor prognosis and lack of effective drugs in STAG2 mutation acute myeloid leukemia. Fangchinoline can inhibit the proliferation and colony formation of AML cell lines SKM-1, Kasumi-6, THP-1 and U-937, induce apoptosis, cell cycle arrest and cell differentiation in these cells, and thus exert an anti-STAG2 mutation acute myeloid leukemia effect.

The invention discloses a quality control method of radix stephaniae tetrandrae decoction pieces, which adopts a liquid chromatography-mass spectrometry method to detect medicinal components in the radix stephaniae tetrandrae decoction pieces. The pharmaceutical composition is prepared from any one or more of tetrandrine, fangchinoline, cycleanine, fangfangphenanthine, oxyfangchine, fangchinoquinine, corynoquinine, eleusine and dicentrine, and the pharmaceutical composition is prepared from any one or more of tetrandrine, fangchinoline, cycleanine, fangchinoline, corynoquinine, eleusine and dicentrine. According to the method, various medicinal components in the radix stephaniae tetrandrae decoction pieces can be detected through specific detection conditions, comprehensive quality control on the radix stephaniae tetrandrae decoction pieces is facilitated, and the possibility of replacing wild radix stephaniae tetrandrae is found through medicinal effect evaluation. Besides, the radix stephaniae tetrandrae decoction pieces are identified by adopting a thin-layer chromatography method before detection, and the identification sensitivity can be improved by adjusting thin-layer chromatography conditions.

The present invention discloses a fangchinoline compound, a preparation method thereof, and an application thereof in the preparation of an anti-Parkinson's drug, and relates to the technical field of anti-Parkinson's drugs. The present invention discloses a fangchinoline compound, a preparation method thereof, and an application thereof in the preparation of an anti-Parkinson's drug, and provides a new compound—a fangchinoline compound and a preparation method thereof. CCK8 experiments have found that the compound is non-toxic to SH-SY5Y cells at a concentration below 40 μM and has no toxicity to MPP. + The induced SH-SY5Y cells exhibited cytoprotective activity far stronger than that of the lead compound, and had important application value in the preparation of anti-Parkinson's drugs. The compounds disclosed in the present invention have the advantages of simple reaction, mild conditions and cheap and readily available reagents in their preparation methods.

The invention provides application of fangchinoline in preparation of a medicine for treating STAG2 mutation acute myelogenous leukemia, and relates to the field of leukemia treatment medicines. According to the application of the fangchinoline in preparation of the medicine for treating the STAG2 mutation acute myelogenous leukemia, aiming at the problems that the STAG2 mutation acute myelogenous leukemia is high in incidence rate, poor in prognosis and lack of effective medicine clinically, proliferation and colony formation of AML cell lines SKM-1, Kasumi-6, THP-1 and U-937 can be inhibited through the fangchinoline, and the STAG2 mutation acute myelogenous leukemia can be treated. The cell apoptosis, cycle arrest and cell differentiation are induced, so that the effect of resisting STAG2 mutation acute myelogenous leukemia is achieved.

The invention discloses an application of fangchinoline alkali in preparation of anti-pseudorabies virus drugs, the fangchinoline alkali has no significant toxicity to cells in a concentration range of 0-5 [mu] M, and the fangchinoline alkali significantly reduces pseudorabies virus infection by inhibiting virus genome replication, protein synthesis and progeny virus titer in a concentration range of 2-4 [mu] M; the fangchinoline can be used as an effective component for developing the anti-pseudorabies virus medicine, and has the advantages of safety, few toxic and side effects, low medicine residue, no pollution and the like.

The invention relates to a method for simultaneously determining seven index components in Fengtongan capsules and constructing a specific chromatogram and application, and belongs to the technical field of detection and analysis. According to the method, a high performance liquid chromatograph and a gradient elution mode are adopted, the contents of phellodendrine (284nm), loganin (236nm), fangchinoline, tetrandrine (280nm), forsythin (277nm), berberine (265nm) and curcumin (430nm) in a prescription can be simultaneously determined by switching different wavelengths under the same elution condition, and a characteristic spectrum (254nm) is constructed. The tested components are well separated, and the practical purposes of multi-component evaluation by one test, high efficiency, low consumption and easiness in popularization are realized. According to the polarity difference of each substance, a gradient elution procedure is adopted to realize separation and accurate detection. So far, no report about simultaneous determination of the seven components in the Fengtongan capsule is found, and the method makes up the blank of quality control and fingerprint spectrum research of various medicinal materials in the prescription.

The application discloses a quality control method of radix stephaniae tetrandrae decoction pieces, adopts liquid chromatography-mass spectrometry to detect the efficacy components in the radix stephaniae tetrandrae decoction pieces, and the efficacy components include any one or several of tetrandrine, fangchinoline, cycilanol, stepholidine, oxystepholidine, stephaoxime, corynoxeine, miliradin and oxymatrine. The specific detection condition can detect multiple efficacy components in the radix stephaniae tetrandrae decoction pieces, which is helpful for comprehensively controlling the quality of the radix stephaniae tetrandrae decoction pieces, and finding the possibility of replacing wild radix stephaniae tetrandrae through efficacy evaluation. In addition, the thin layer chromatography is used to identify the radix stephaniae tetrandrae decoction pieces before detection, and the identification sensitivity can be improved by adjusting the thin layer chromatography condition.

The present invention relates to a method for simultaneously determining seven index components in Fengtong'an capsules and constructing a characteristic spectrum and its application, belonging to the field of detection and analysis technology. The present invention adopts a high performance liquid chromatograph and a gradient elution method. By switching different wavelengths under the same elution conditions, the contents of phellodendronine (284nm), loganin (236nm), fangchinoline, tetrandrine (280nm), forsythin (277nm), berberine (265nm), and curcumin (430nm) in a prescription can be simultaneously determined and a characteristic spectrum (254nm) can be constructed. The measured components are well separated, achieving the practical purpose of one measurement and multiple evaluations, high efficiency, low consumption and easy popularization. According to the polarity differences of each substance, a gradient elution program is adopted to achieve separation and accurate detection. To date, no report on the simultaneous determination of these seven components in Fengtong'an capsules has been found. This method fills the gap in the quality control of multiple medicinal materials in prescriptions and the research on fingerprints.

The invention relates to a compound preparation for treating salmonella infection, which comprises rutin and fangchinoline, and the concentration ratio of the fangchinoline to the rutin is 1: 2. The compound preparation plays an antibacterial role through an anti-virulence strategy and a host-oriented strategy, remarkably reduces the bacteria loading amount of salmonella in tissue organs and intestinal contents of mouse and chick models, improves tissue pathological damage, and has good safety. The compound preparation disclosed by the invention provides an efficient and safe novel scheme for treating salmonella infection.

The application discloses application of fangchinoline in prevention and treatment of salmonella infection. The fangchinoline is an isoquinoline alkaloid and is a host-directed therapy natural compound. The application discloses that the fangchinoline has a strong effect on treatment of salmonella infection diseases in vivo and in vitro, and the effect is specifically shown as that the fangchinoline can effectively reduce the bacterial amount of intracellular infection bacteria. The fangchinoline administration can significantly reduce the pathogenic bacteria load in the liver, spleen, colon, cecum and ileum of mice, and reduce the pro-inflammatory factor level of the organism. The safety in vivo and in vitro shows that the fangchinoline has no any toxic side effect under the test dose. In addition, the fangchinoline has significant synergistic antibacterial activity in combination with fluoroquinolones, which is shown as reduction of intracellular salmonella infection bacteria number and reduction of the pathogenic bacteria load in the liver, spleen and colon of mice. The application provides a new perspective for development of a new anti-infection drug, and also provides a new idea for prevention and control of the increasingly serious salmonella infection.